Immutep (NASDAQ:IMMP - Get Free Report) had its price objective decreased by equities research analysts at Robert W. Baird from $7.00 to $6.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Robert W. Baird's target price suggests a potential upside of 116.61% from the company's previous close.
https://www.marketbeat.com/instant-alerts/nasdaq-immp-lower-price-target-2024-06-27/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.